Friday, April 22, 2011

Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers




April 22, 2011 By Robert Graham Reporting from College of Biblical
Studies Scholarship 2011 Awards Dinner -----< Business--Wire>


Fathers are twice likely to pass on a genetic breast cancer mutation as Mothers.

Your human genome is a catalog of all the genetic information contained in your human cells. We all have from 25,000 to 40,000 genes - each gene is chemical part contributing to your life's biological processes.

Gen Connect scientist with genomics use unimagined detail to learn how the body grows and gets old,and why it stays healthy or falls ill. With this knowledge GenC gives doctors the ability to predict, early in life, a person's risk for disease.

GenConnect purpose is to decipher the human genome. Scientist and researchers can have access to Genc's breast cancer data by making the Genc scientific out comes available with a paid subscription to many universities.

Our genetic makeup is not that different from that of other mammals. we have 300 genes that are not in mice, also there are 60 million DNA-letter differences between people and chimps.

We all are 99.9 percent identical. All of us are composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes.

The human genome is composed of an estimated 3 billion letters of DNA code, arranged in 23 pairs of long chains called chromosomes. For an example a human male showing 46 chromosomes including XY sex chromosomes Humans
(Homo sapiens) are a eukaryotic species A human has 46 chromosomes (44 autosomes and 2 sex chromosomes with an XY sex determination system) At present estimate humans have approximately 20000-25000 genes Humans share 985% of their DNA with their closest living evolutionary relative the bonobos.

With all of this information Genc is able to extend life for many women with breast cancer.

With a new Down Towm Houston office
Australian-based Biotech Engineering Firm, GenConnect , Inc., today announced the appointment Mercedes Ramos to serve as the company's Director of corporate development. Mercedes primary role will be to identify and develop creative technical resource applications to grow existing and new biotech companies and support the company's growing genomics management programs. Ramos responsibilities also include leading business development teams that target the medical electronics market and supporting growth in the genomics market segment. Ramos appointment signals a tactical evolution of executive structure that further differentiates GenConnect among Medical research as the company focuses its company expertise and Bioinfomatics increasingly on specific markets. The timing of the appointment also capitalizes on the company's recent ISO certifications for medical and device sales.

GenConnect corporate development program is further strengthened by the recent hiring of Vikki Waterford, a thirty-one year medical distribution industry veteran who will support Mercedes as business development manager for manufacturer's rep, channel partner and supplier programs. Collectively, these moves continue the successful play out of the company's strategic growth plan. Ms. Waterford brings extensive expertise in sales and materials management to her position. She has held senior management positions at a number of Tier-1 Medical distributors and has gained an in-depth knowledge of nearly all aspects of the industry.

Waterford joined World Micro in 2004, bringing twenty-four years of corporate development experience. Prior to this appointment he was director of corporate development responsible for bringing an eight million dollar embedded computing business unit to the company's already diverse portfolio. He was instrumental in creating GenConnect "Hybrid Business Model" marketing strategy that helped the company create industry awareness of the distinct differences between brokers and the new class of medical device distributors, who like GenConnect, focus increasingly on Biotech Engineering Management, and quality initiatives.

GenConnect corporate development program is proud to welcome its legal intern, Yolanda Buckner. Yolanda is a second year law student who will work closely with Mercedes by identifying and researching legal issues that may arise in Mercedes’s efforts to grow the genomics management programs.

Under the supervision of Hybrid Medical Analytics’s in house counselors, Yolanda will play a large role in staying current with the new and existing HIPAA laws. She will also play a vital role in ensuring that GenConnect’s initiatives are in compliance with the Texas laws. In return, her efforts will ensure that GenConnect’s initiatives have been filtered through the appropriate governing laws, thereby furthering the business development of GenConnect.

Thursday, April 7, 2011

Genomics help Women of Color with Breast Cancer


April 7, 2011 By Robert Graham Reporting from AACR 102nd Annual Meeting 2011 Orlando, FL -----< Business--Wire>


Genomics help Women of Color with Breast Cancer

Genomics help women understand the genetic etiology of Breast Cancer and chronic diseases, we interviewed GenConnect Inc Chief Science Officer Joan Hilsenrath on GenC genomics objectives and how GenC pursues and accomplished results in multiple human populations.

Understanding the genetics of Breast Cancer diseases involves:
• locating and characterizing genes underlying the common chronic diseases,
• characterizing the extent and utility of DNA variation within and among populations and determining how these patterns of variation evolved in both time and space,
• Establishing the impact of gene variation on the health of individuals, families and populations.


At each step, the role of computational and biotech information approaches and resources are preeminent. Hilsenrath says that they are the world’s preeminent research unit focusing on the genetics of common chronic breast cancer disease.

GenConnect Inc researchers have used whole-genome sequencing to catalog the genetic alterations in tumors from patients with estrogen receptor (ER)-positive breast cancer. The goal of the study is to identify genetic factors that explain why some tumors respond to estrogen-lowering drugs and others do not.

GenConnect Inc says Women with ER-positive breast cancer take estrogen-lowering drugs, such as tamoxifen which is fifty percent toxic or aromatase inhibitors, to slow the growth of tumors, make the tumors easier to remove surgically, or prevent the re-growth of tumors after surgery or radiation.

In addition to commonly mutated genes included her-2 TP53. and TP3. GenC discovered, MAP3K1, a tumor-suppressor gene, was defective in 10 percent of patients. This was the first time the gene has been associated with breast cancer. The technology used to make this discovery

Genomics provide a faster cheaper more effective way to detect the Her2 gene by using Semiconductor Sequencing. A example of this technique is Semiconductor Sequencing uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. GenC chips are designed like any other semiconductor chips. Yes with a simple blood test women of color can reduce breast cancer. If someone in your family has a history of breast cancer as your oncologist for a Genomics Test.


Hilsenrath noted that Stand Up To Cancer Innovative Research Grants are special in that they allow some of the best and brightest young researchers across various disciplines to step out of their comfort zones and attempt to make major breakthroughs in the field with bold genomics research projects in the area of Breast Cancer in women of color.

Congress is looking at a $1.6 billion cut to NIH is on the table. With cutting lifesaving biomedical research would be devastating to the millions of Americans and their families affected by cancer.